This is the authors' abstract. We don't add key points for this paper.
Citrullus ecirrhosus is traditionally used to treat gastrointestinal track diseases in Botswana due to its phytocompounds. Our study evaluated the antioxidant capacity, characterized phytocompounds and their HMG-CoA reductase inhibitory potential of C. ecirrhosus seed powder (CESP). Water, methanol, ethyl acetate, chloroform and hexane were used to extract CESP’s phytocompounds. The antioxidant activity using total antioxidant capacity, 2,2-diphenyl-1-picrylhydrazyl and 2,2’-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) assays revealed significantly higher (p < 0.05) antioxidant activity in the methanolic and water extracts compared to the other extracts. The methanolic and water extracts also showed higher (p < 0.05) total phenolic and flavonoid content compared to the other extracts. Using Gas Chromatography-Mass Spectroscopy (GC-MS), the major phytocompound identified were Hexadecanoic acid, Vanillin lactoside, Octadecanoic acid, 9,10-Secocholesta-5,7,10(19)-triene-3,24,25-triol (3β,5Z,7E), and 2-Methoxy-4-vinylphenol. Phytocompounds identified through GC-MS were subjected to in silico molecular docking to understand the mechanism of HMG CoA reductase’s anti-atherogenic action. Vanillin lactoside had high binding affinities for HMG-CoA reductase of −8.2 kcal/mol with interactions including conventional hydrogen bond and carbon hydrogen bond. Our findings offer significant insights into the antioxidant properties and HMG-CoA reductase inhibitory potential of C. ecirrhosus. Additional studies are needed to understand the mechanism of action, potential in vivo and clinical outcomes of C. ecirrhosus.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Kambasiya et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: